# Safety and Immunogenicity of a Candidate MERS-CoV Vaccine (MERS001)

> **NCT03399578** · PHASE1 · TERMINATED · sponsor: **University of Oxford** · enrollment: 29 (actual)

## Conditions studied

- MERS (Middle East Respiratory Syndrome)

## Interventions

- **BIOLOGICAL:** ChAdOx1 MERS

## Key facts

- **NCT ID:** NCT03399578
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-14
- **Primary completion:** 2021-09-17
- **Final completion:** 2021-09-17
- **Target enrollment:** 29 (ACTUAL)
- **Why stopped:** The scientific questions proposed remain relevant, but will now be addressed in a larger phase II immunogenicity trial of the ChAdOx1 MERS vaccine given at 2 doses.
- **Last updated:** 2021-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03399578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03399578, "Safety and Immunogenicity of a Candidate MERS-CoV Vaccine (MERS001)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03399578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*